Aripiprazole (1,1,2,2,3,3,4,4-d8)

• CAT Number: S000253
• CAS Number: 1089115-04-7
• Molecular Formula: C23H19D8Cl2N3O2
• Molecular Weight: 456.43
• Purity: ≥95%
• IUPAC Name: 7-[1,1,2,2,3,3,4,4-octadeuterio-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
• InChI: InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)/i1D2,2D2,10D2,15D2
• InChIKey: CEUORZQYGODEFX-BQLKVSHCSA-N
• SMILES: [2H]C([2H])(C([2H])([2H])C([2H])([2H])OC1=CC2=C(CCC(=O)N2)C=C1)C([2H])([2H])N3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl

Aripiprazole (1,1,2,2,3,3,4,4-d8) (CAS: 1089115-04-7), a premium pharmaceutical research compound designed for advanced psychopharmacological studies. As a deuterated analog of Aripiprazole, it offers enhanced stability and improved pharmacokinetic properties. Aripiprazole (1,1,2,2,3,3,4,4-d8) is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel antipsychotic therapies. Trusted by leading laboratories, Aripiprazole (1,1,2,2,3,3,4,4-d8) is your go-to solution for cutting-edge mental health research. Unlock new possibilities in the treatment of psychiatric disorders with Aripiprazole (1,1,2,2,3,3,4,4-d8), where innovation meets reliability.

Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]

[2]. Stip E, Tourjman V. et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.
[Content Brief]

[3]. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.
[Content Brief]

[4]. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
[Content Brief]

[5]. Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.
Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T.
Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Biopharm Drug Dispos. 2012 Jul 27. doi: 10.1002/bdd.1801.
[Content Brief]